Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system

Original Submission
19 Sep 2022 Submitted Original manuscript
2 Feb 2023 Reviewed Reviewer Report
7 Feb 2023 Reviewed Reviewer Report
2 Mar 2023 Reviewed Reviewer Report
3 Apr 2023 Author responded Author comments - CHEN ZHU
Resubmission - Version 2
3 Apr 2023 Submitted Manuscript version 2
17 Apr 2023 Reviewed Reviewer Report
4 May 2023 Reviewed Reviewer Report
22 May 2023 Reviewed Reviewer Report
14 Jun 2023 Author responded Author comments - CHEN ZHU
Resubmission - Version 3
14 Jun 2023 Submitted Manuscript version 3
20 Jun 2023 Reviewed Reviewer Report
23 Jun 2023 Reviewed Reviewer Report
2 Aug 2023 Author responded Author comments - CHEN ZHU
Resubmission - Version 4
2 Aug 2023 Submitted Manuscript version 4
22 Aug 2023 Reviewed Reviewer Report
31 Aug 2023 Author responded Author comments - CHEN ZHU
Resubmission - Version 5
31 Aug 2023 Submitted Manuscript version 5
Publishing
6 Sep 2023 Editorially accepted
11 Oct 2023 Article published 10.1186/s12913-023-10037-1

You can find further information about peer review here.

Back to article page